This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Helmholtz-Zentrum Dresden-Rossendorf - Institute of Radiopharmaceutical Cancer Research, Instituto Portugues De Oncologia Do Porto Fg, Epe, Universidade Nova De Lisboa. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 7 Years Active: 2022
Title: Innovator Luís Carlos Oliveira Lima: Pioneering Cancer Research with L2A5 Antibody
Introduction
Luís Carlos Oliveira Lima, an innovative scientist based in Caparica, Portugal, has made significant contributions to cancer research through his groundbreaking invention of the L2A5 antibody. This invention holds promise for improving detection, treatment, and prevention methodologies in oncology, representing a significant advancement in the field.
Latest Patents
Luís Carlos Oliveira Lima holds a patent for his invention of the L2A5 antibody or functional fragment thereof against tumor antigens. This invention provides a unique group of antibodies directed against specific cancer-related antigens. The patent comprises nucleotide sequences derived from the L2A5 monoclonal antibody, making it a pioneering effort in the identification and characterization of antibodies in cancer therapy. The antibody's design includes a variable heavy chain domain and a variable light chain domain, characterized by an unprecedented amino acid sequence. This invention has vital implications for enhancing diagnostic techniques and therapeutic strategies in treating various human diseases, particularly cancer.
Career Highlights
Throughout his professional journey, Luís Carlos Oliveira Lima has collaborated with esteemed institutions such as Nova University of Lisbon, where he contributed to academic research and innovation. Additionally, he worked at the Portuguese Institute of Oncology in Porto, where he engaged in concerted efforts aimed at advancing cancer treatment methodologies. His career reflects a steadfast commitment to scientific inquiry and innovation.
Collaborations
Luís Carlos Oliveira Lima has collaborated with notable professionals in his field, including Paula Alexandra Quintela Videira and Carlos Manuel Mendes Novo. These collaborations have facilitated the sharing of knowledge and expertise, further enriching the research landscape within which he operates.
Conclusion
Luís Carlos Oliveira Lima stands out as a key innovator in cancer research, with his L2A5 antibody representing a significant leap forward in the quest to combat cancer effectively. Through his unwavering dedication and collaborative spirit, he continues to contribute meaningfully to the scientific community, paving the way for future advancements in the field of oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile